Kim Helen Susan insider trades
Kim Helen Susan has filed 8 Form 4s with the SEC that we hold, for Prothena Corp Public LTD Co (PRTA) (Director), AMTI (Director) and Aktis Oncology, Inc. (AKTS) (Director, 10% owner). Across all of them we count 2 purchases worth $15.0M and 9 sales worth $9.4M reported on Form 4. In the last 12 months: 2 purchases ($15.0M) and 0 sales ($0). The largest single trade was a purchase of 812,455 shares of Aktis Oncology, Inc. worth $14.6M, dated 2026-01-12. The first filing on our record is dated 2021-07-06 and the latest 2026-01-12.
Prothena Corp Public LTD Co (PRTA)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
AMTI
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-07-02 | S, sale reported on Form 4 | 198,759 | $8.6M | 2021-07-06 |
| 2021-07-02 | S, sale reported on Form 4 | 1,241 | $57.5K | 2021-07-06 |
| 2021-08-24 | S, sale reported on Form 4 | 3 | $90 | 2021-08-25 |
| 2021-08-24 | S, sale reported on Form 4 | 505 | $15.2K | 2021-08-25 |
| 2021-08-25 | S, sale reported on Form 4 | 9,478 | $285.1K | 2021-08-25 |
| 2021-08-26 | S, sale reported on Form 4 | 13,505 | $406.8K | 2021-08-27 |
| 2021-08-26 | S, sale reported on Form 4 | 558 | $17.3K | 2021-08-27 |
| 2021-08-27 | S, sale reported on Form 4 | 250 | $7.9K | 2021-08-27 |
| 2021-08-27 | S, sale reported on Form 4 | 701 | $21.6K | 2021-08-27 |
Aktis Oncology, Inc. (AKTS)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-01-12 | P, purchase reported on Form 4 | 22,545 | $405.8K | 2026-01-12 |
| 2026-01-12 | P, purchase reported on Form 4 | 812,455 | $14.6M | 2026-01-12 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1422772) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms